valu usd unless otherwis note
stock price appreci
view share trade discount peer make
attract valuat standpoint howev share
close valuat gap versu sector manag must deliv
believ lower half revenu guidanc
realist mid-single-digit growth cvg rtg mitg segment
low-double-digit growth diabet group take us low end
guidanc high-single-digit growth cvg
mid-teen growth dg push compani growth rate toward
high end revenu growth forecast appear stretch
us revenu estim impli oper
growth includ currenc forecast non-gaap ep
growth compar cc basi yield rang
cardiac structur heart csh key cvg sale growth
forecast revenu growth csh busi
doubl sequenti
tavr sale jump intern tavr sale climb
launch evolut label expans includ
intermedi risk aortic stenosi patient growth driver
revenu trend drug elut stent improv follow launch
resolut onyx japan report market share gain
product categori
recoveri diabet group take hold dg better
manag forecast quarter earlier revenu
y/i revenu patient buy minim
 ahead sensor avail help mitig sale
declin made good progress build sensor capac
compani expect fulli abl meet patient demand
anoth boost diabet busi select
help patient transit away anima pump post decis
exit insulin pump market patient potenti futur
custom mdt minim
estim look reason base initi comment
next year outlook mid-single-digit cc revenu growth margin
expans pertin comment preliminari financi
guidanc call forecast cc revenu growth
forecast reli recoveri revenu growth
continu strong intern perform start point
ep growth rang appear reason impli
rang rbce increas
price target appli target price-to-earnings
price prior trade day market close estimate unless otherwis note
mid-point guidanc appear like best-
revenu growth ep growth
manag forecast stronger growth
base time new product spend
launch guidanc impli compar cc growth
next two quarter
estim look reason base initi
comment next year outlook mid-single-digit cc
revenu growth oper margin expans
two pertin comment financi guidanc
start point ep growth
rang appear reason impli rang
intermediate-risk label expans prove
import catalyst tavr market growth interim result
surtavi trial present annual meet
american colleg cardiolog result
patient present tct show
surtavi met primari end point non-inferior
surgeri furthermor corevalve/corevalv evolut
result trend favor surgeri sever
import clinic procedur outcom receiv
fda approv new indic juli
number busi within segment
well restor therapi group rtg
neurovascular neurosurgeri advanc energi
worth highlight spine recov minim
invas therapi group mitg launch new
product advanc advanc stapl
bloomberg capit market estim upside/downside/target
price target base price-to-earnings multipl
ep y/i mdt current price-to-earnings multipl
ep estim key assumpt
underli ep estim mid-single-digit revenu
compound-annual-growth-rate next three fiscal year exclud
neg impact hurrican maria
relat disrupt basi point oper
margin expans three year excess free
cash flow deploy primarili debt repay
upsid scenario base price-to-earnings multipl
cy ep key assumpt underli
ep estim revenu compound-annual-growth-rate next three
fiscal year achiev combin
accret superior perform key product
stent leadless pacemak brain therapi diabet
basi point oper margin expans
three year
downsid scenario base price-to-earnings multipl
cy ep key assumpt underli ep
estim revenu compound-annual-growth-rate next three fiscal
year basi point oper margin
expans three year meaning
price target base ep estim y/i
reli success new product launch past month acceler growth
target multipl lower averag price-to-earnings large-cap
med-tech peer trade around consensu estim reflect slower
growth base forecast peer group compani price target basi
outperform rate
risk rate price target
lacklust new product cycl sale growth increasingli support
stand-alon new product cycl includ attain performa quadripolar crt-d
reveal linq micra pacemak admir dcb corevalv evolut estim could
neg affect sale new product come expect
inabl achiev target cost save manag believ achiev least
pre-tax cost synergi end cost synergi fail
materi project ep growth estim could high
risk price target rate includ potenti regulatori delay reject
failur devic clinic trial weaken demand key market price pressur
weak util trend fx
lead world-wide medic technolog compani engag manufactur
sell device-bas medic therapi compani oper four segment cardiac
vascular group restor therapi group diabet group minim invas
million except ep fy april
